Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Aug;41(1):114-22.
doi: 10.1007/s12016-011-8254-2.

Therapeutic approaches in hereditary angioedema

Affiliations
Review

Therapeutic approaches in hereditary angioedema

Sabina Antonela Antoniu. Clin Rev Allergy Immunol. 2011 Aug.

Abstract

Hereditary angioedema (HAE) is characterized by acute attacks of edema with multiple localizations, the laryngeal angioedema being the most potentially lethal. In HAE, C1-INH impairments cause episodic increase in kallikrein activity leading to attacks of angioedema. Several therapies have recently become available to treat or to prevent HAE attacks, and others are under evaluation for this indication. Plasma-derived C1-INH, bradykinin receptor antagonists (icatibant), kallikrein inhibitors (ecallantide), or recombinant C1-INH is authorized on the market for HAE attack therapy or prophylaxis. Some of these compounds can be used exclusively to treat HAE attacks, whereas others can also be used as prophylactic therapies. Such therapies, although not available worldwide, can improve disease outcome due to their different mechanisms of action.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Clin Invest. 2002 Apr;109(8):1057-63 - PubMed
    1. J Biol Chem. 1990 Jun 25;265(18):10786-91 - PubMed
    1. J Clin Invest. 1990 Apr;85(4):1215-20 - PubMed
    1. Br J Pharmacol. 1991 Mar;102(3):769-73 - PubMed
    1. N Engl J Med. 2010 Aug 5;363(6):513-22 - PubMed

MeSH terms

LinkOut - more resources